What is the current valuation of the US Tuberculosis Vaccine Treatment Market?

As of 2024, the market valuation was 203.7 USD Million. Read More

What is the projected market size for the US Tuberculosis Vaccine Treatment Market by 2035?

The market is expected to reach a valuation of 302.4 USD Million by 2035. Read More

What is the expected CAGR for the US Tuberculosis Vaccine Treatment Market during the forecast period?

The market is projected to grow at a CAGR of 3.66% from 2025 to 2035. Read More

Which companies are the key players in the US Tuberculosis Vaccine Treatment Market?

Key players include Merck & Co., GlaxoSmithKline, Sanofi, Pfizer Inc., Bavarian Nordic, AstraZeneca, Novartis, and Johnson & Johnson. Read More

What are the main applications of tuberculosis vaccines in the market?

The main applications include Preventive Vaccination, Therapeutic Vaccination, Post-Exposure Prophylaxis, and Research and Development. Read More

How does the market segment by application perform in terms of valuation?

In 2024, Preventive Vaccination was valued at 60.0 to 90.0 USD Million, while Therapeutic Vaccination ranged from 50.0 to 70.0 USD Million. Read More

What are the primary end-use segments in the US Tuberculosis Vaccine Treatment Market?

The primary end-use segments are Hospitals, Clinics, Research Institutions, and Public Health Organizations. Read More

What is the valuation range for hospitals in the US Tuberculosis Vaccine Treatment Market?

In 2024, hospitals were valued between 60.0 and 90.0 USD Million. Read More

Which vaccine types are included in the US Tuberculosis Vaccine Treatment Market?

The market includes Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, and DNA Vaccine. Read More

What is the expected performance of the distribution channels in the market?

In 2024, Pharmacies were valued at 60.0 to 90.0 USD Million, indicating a strong distribution channel. Read More

US Tuberculosis Vaccine Treatment Market

ID: MRFR/Pharma/17463-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Tuberculosis Vaccine Treatment Market Research Report By Type Of Test (Tuberculin Skin Test, TB Blood Tests, Igras), By Type Of TB Vaccine (Immunotherapeutic Vaccines, Booster Vaccines) and By End Users (Hospitals, Private Clinics) - Growth & Industry Forecast 2025 To 2035

US Tuberculosis Vaccine Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Preventive Vaccination
  2. 4.1.2 Therapeutic Vaccination
  3. 4.1.3 Post-Exposure Prophylaxis
  4. 4.1.4 Research and Development
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Clinics
  3. 4.2.3 Research Institutions
  4. 4.2.4 Public Health Organizations
3. 4.3 Healthcare, BY Vaccine Type (USD Million)
  1. 4.3.1 Live Attenuated Vaccine
  2. 4.3.2 Inactivated Vaccine
  3. 4.3.3 Subunit Vaccine
  4. 4.3.4 DNA Vaccine
4. 4.4 Healthcare, BY Distribution Channel (USD Million)
  1. 4.4.1 Direct Sales
  2. 4.4.2 Online Sales
  3. 4.4.3 Pharmacies
  4. 4.4.4 Healthcare Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co. (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GlaxoSmithKline (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer Inc. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bavarian Nordic (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY END USE
4. 6.4 US MARKET ANALYSIS BY VACCINE TYPE
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY END USE, 2026-2035 (USD Million)
  3. 7.2.3 BY VACCINE TYPE, 2026-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

Preventive Vaccination
Therapeutic Vaccination
Post-Exposure Prophylaxis
Research and Development

Healthcare By End Use (USD Million, 2026-2035)

Hospitals
Clinics
Research Institutions
Public Health Organizations

Healthcare By Vaccine Type (USD Million, 2026-2035)

Live Attenuated Vaccine
Inactivated Vaccine
Subunit Vaccine
DNA Vaccine

Healthcare By Distribution Channel (USD Million, 2026-2035)

Direct Sales
Online Sales
Pharmacies
Healthcare Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”